Post-Market Clinical Investigation of the FemoSeal™ VCS: A Prospective,

Status Completed

Clinical Trial Summary

The study aims to further demonstrate the safety and effectiveness of the FemoSeal™ VCS in achieving hemostasis following percutaneous endovascular procedures performed via the common femoral artery (CFA) access site. This study is conducted in real-world subjects according to the FemoSeal™ VCS instruction for use (IFU), as part of the study device post-market clinical follow up surveillance plan and prospective clinical evidence collection.

Clinical Trial Description

The proposed Post-Market Clinical Follow-up study is a Prospective, Multi-Center, Observational Study, aiming to further demonstrate the safety and effectiveness of the FemoSealTM VCS in achieving hemostasis of common femoral artery (CFA) access site in real-world subjects undergoing percutaneous endovascular procedures. 230 patients will be enrolled at up to 6 European sites. Follow-ups are scheduled at 30 days (±7 days) by hospital visit or telephone call. The sponsor shall provide training and the necessary guidelines to assist each investigation site on the data collection in the eCRF. Each site is responsible to report the available data requested by the CIP. In order to ensure data quality, validation & consistency, edit checks will be designed during database development. Data Management team and the study monitors will be responsible to review the data and raise queries in the eCRF. Data cleaning will be done in regular intervals specified in Data Monitoring Plan. The final clean standardised datasets will be available prior to database lock for data analysis. An audit trail logging all data entered and edited is available within the EDC system. All source documents are maintained in the hospital files ready for inspection by the Sponsor and regulatory authorities upon request. The Sponsor will inform the investigator of the time period for retaining these records as per applicable regulatory requirements. The study will be monitored at all stages of its development by study monitors appointed by the sponsor. Study monitors are designated as Sponsor representatives and are assigned to oversee the conduct and progress of the study at each site in accordance with the Monitoring Plan established for this clinical investigation. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05027698
Study type	Observational
Source	Terumo Europe N.V.
Contact
Status	Completed
Phase
Start date	December 27, 2021
Completion date	August 3, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05335525` - Post-market Clinical Investigation of the Angio-Seal™ VIP VCD (ANGIO-SEAL CLOSE)
Active, not recruiting	`NCT01903044` - Safety and Efficacy of Autologous Bone Marrow Stem Cells for Lower Extremity Ischemia Treating	Phase 1/Phase 2
Completed	`NCT02228564` - BARD® Study of LIFESTREAM™ Balloon Expandable Covered Stent Treating Iliac Arterial Occlusive Disease	N/A
Completed	`NCT02271529` - Zilver PTX Delivery System	N/A
Recruiting	`NCT02054871` - RCT to Evaluate the Renal Protective Effects of Remote Ischaemic Preconditioning in Peripheral Angioplasty	N/A
Completed	`NCT00822172` - Evaluation of Cilostazol in Combination With L-Carnitine	Phase 4
Completed	`NCT00574782` - Evaluation of the Efficacy of Rosuvastatin in Daily Practice in Untreated High Risk Patients (CHALLENGE)	N/A
Completed	`NCT00029991` - Extract of Ginkgo Biloba (EGB 761) and Vascular Function	Phase 1/Phase 2
Completed	`NCT01355406` - Evaluation of Safety and Efficacy of the FlexStent® Femoropopliteal Self-Expanding Stent System	N/A
Recruiting	`NCT05804097` - Does Increasing Oxygen Nurture Your Symptomatic Ischemic Ulcer Sufficiently?	Phase 4
Recruiting	`NCT03638115` - The VaSecure BTK Study	N/A
Active, not recruiting	`NCT03241459` - Safety and Efficacy of the SurVeil™ Drug-Coated Balloon	N/A
Active, not recruiting	`NCT01661231` - Study to Determine the Performance of the Astron and Pulsar-18 Stents in Europe	N/A
Completed	`NCT01722877` - JetStream (JS) Atherectomy in Femoropopliteal In-Stent Restenotic Lesions	N/A
Completed	`NCT01444378` - Absolute Pro® MOMENTUM™	N/A
Completed	`NCT00753337` - The ACTIVE (Use of the Assurant® Cobalt Iliac Stent System in the Treatment of Iliac Vessel Disease) Study	N/A
Completed	`NCT00538226` - Evaluation of the Effect of the Flowaid Device in Increasing Local Circulation in the Leg	Phase 1
Completed	`NCT00593385` - Atrium iCAST Iliac Stent Pivotal Study	N/A
Recruiting	`NCT00385385` - RESTORE-IT-Study of Rifalazil in Chlamydia Pneumoniae Seropositive Patients With a History of Atherosclerotic Disease	Phase 2
Completed	`NCT00392509` - ALD-301 for Critical Limb Ischemia, Randomized Trial	Phase 1/Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Post-Market Clinical Investigation of the FemoSeal™ VCS: A Prospective, Multi-Center Observational European Study — FEMOSEAL CLOSE

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms